Hepatitis c virus: A review of treatment guidelines, cost-effectiveness, and access to therapy

Journal of Clinical and Translational Hepatology

Volumn 4, Issue 4, 2016, Pages 310-319

  Lynch, Shaina M ^a   Wu, George Y ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Drug therapy; HCV; Health care costs; Hepatitis C

Indexed keywords

EID: 85032721938     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2016.00027     Document Type: Article

References (44)

1. World Health Organization. Guidelines for the screening, care, and treatment of persons with hepatitis C infection. Available from: http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua, accessed April 2014.
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107–115. doi: 10.1111/j.1469-0691.2010.03432.x.
3. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160: 293–300. doi: 10.7326/M13-1133.
4. Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insur-ance. Clin Gastroenterol Hepatol 2016;14:1035–1043. doi: 10.1016/j. cgh.2016.03.040.
5. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57:1333–1342. doi: 10.1002/hep.26141.
6. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 2015;62:932–954. doi: 10.1002/hep.27950.
7. Mahajan R, Liu SJ, Klevens RM, Holmberg SD. Indications for testing among reported cases of HCV infection from enhanced hepatitis surveillance sites in the United States, 2004–2010. Am J Public Health 2013;103:1445–1449. doi: 10.2105/AJPH.2013.301211.
8. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008. Hepatology 2012;55:1652–1661. doi: 10.1002/hep.25556.
9. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015;63:199–236. doi: 10.1016/j. jhep.2015.03.025.
10. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendations for hepatitis C prevention, epi-demiology, and laboratory testing. Hepatol Int 2016;10:681–701. doi: 10.1007/s12072-016-9736-3.
11. Wedemeyer H, Dore GJ, Ward JW. Estimates on HCV disease burden world-wide-filling the gaps. J Viral Hepat 2015;22 Suppl 1:1–5. doi: 10.1111/jvh.12371.
12. World Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Available from: http://www. who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/, accessed April 2016.
13. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available from: http://hcvguidelines.org/sites/default/files/HCV-Guidance:October_2016_a.pdf, accessed September 2016.
14. Badri PS, King JR, Polepally AR, McGovern BH, Dutta S, Menon RM. Dosing recommendations for concomitant medications during 3D anti-HCV therapy. Clin Pharmacokinet 2016;55:275–295. doi: 10.1007/s40262-015-0317-8.
15. U.S. Food and Drug Administration. FDA approves Epsclusa for treatment of chronic Hepatitis C virus infection. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm508915.htm, accessed June 2016.
16. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, et al. APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016;10:702–726. doi: 10.1007/s12072-016-9717-6.
17. Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, et al. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat 2013;20:745–760. doi: 10.1111/jvh.12173.
18. Stepanova M, Younossi ZM. Interferon-free regimens for chronic hepatitis C: barriers due to treatment candidacy and insurance coverage. Dig Dis Sci 2015;60:3248–3251. doi: 10.1007/s10620-015-3709-6.
19. Woolston SL, Kim HN. Cost and access to direct-acting antiviral agents. Available from: http://www.hepatitisc.uw.edu/go/evaluation-treatment/cost-access-medications/core-concept/all#cost-effectiveness-direct-acting-antiviral-agents, accessed July 2016.
20. World bank country and lending groups. Available from: https://datahelp-desk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.
21. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut 2015;64:1824–1833. doi: 10.1136/gutjnl-2015-310421.
22. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin Infect Dis 2015;60:1829–1836. doi: 10.1093/cid/civ197.
23. Sumner A. The new bottom billion: what if most of the world’s poor live in middle income countries? CGD Brief. Available from: http://www.cgdev.org/sites/default/files/1424922_file_Sumner_brief_MIC_poor_FINAL.pdf, accessed March 2011.
24. Do A, Mittal Y, Liapakis A, Cohen E, Chau H, Bertuccio C, et al. Drug author-ization for sofosbuvir/ledipasvir (harvoni) for chronic HCV infection in a real-world cohort: a new barrier in the HCV care cascade. PLoS One 2015;10: e0135645. doi: 10.1371/journal.pone.0135645.
25. Chak EW, Sarkar S, Bowlus C. Improving healthcare systems to reduce healthcare disparities in viral hepatitis. Dig Dis Sci 2016;61:2776–2783. doi: 10.1007/s10620-016-4205-3.
26. Saab S, Jimenez M, Fong T, Wu C, Bau S, Jamal Z, et al. Accessibility to oral antiviral therapy for patients with chronic hepatitis C in the United States. J Clin Transl Hepatol 2016;4:76–82. doi: 10.14218/JCTH.2016.00011.
27. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215–223. doi: 10.7326/M15-0406.
28. Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state medicaid programs. Ann Intern Med 2015; 163:226–228. doi: 10.7326/M15-0320.
29. Edlin BR. Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infect Dis 2016;16:e196–e201. doi: 10.1016/S1473-3099(16)30005-6.
30. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer 2016;11:24. doi: 10.1186/s13027-016-0071-z.
31. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology 2015;61:1860–1869. doi: 10.1002/hep.27736.
32. Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman BR, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med 2015;162:619–629. doi: 10.7326/M14-1313.
33. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med 2015;162:397–406. doi: 10.7326/M14-1336.
34. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis 2015;61:157–168. doi: 10.1093/cid/civ220.
35. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 2015;162:407–419. doi: 10.7326/M14-1152.
36. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2015;41:544–563. doi: 10.1111/apt.13081.
37. Chhatwal J, He T, Lopez-Olivo MA. Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals. Pharmacoeconomics 2016;34:551–567. doi: 10.1007/s40273-015-0373-9.
38. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next steps toward eradication of hepatitis C in the era of direct acting anti-virals. Hepat Mon 2016;16:e37089. doi: 10.5812/hepatmon.37089.
39. Graham CS, Swan T. A path to eradication of hepatitis C in low-and middle-income countries. Antiviral Res 2015;119:89–96. doi: 10.1016/j. antiviral.2015.01.004.
40. Saag MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. Clin Infect Dis 2015;61:169–170. doi: 10.1093/cid/civ221.
41. Feld JJ, Zeuzem S. Sofosbuvir and Velpatasvir for patients with HCV infec-tion. N Engl J Med 2016;374:1688–1689.
42. Curry MP, Charlton M. Sofosbuvir and velpatasvir for patients with HCV infec-tion. N Engl J Med 2016;374:1688.
43. Foster GR, Mangia A, Sulkowski M. Sofosbuvir and velpatasvir for patients with HCV infection. N Engl J Med 2016;374:1687–1688. doi: 10.1056/NEJMc1601160.
44. Hill A, Khoo S, Fortunak J, Simmons B, Ford N. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014;58:928–936. doi: 10.1093/cid/ciu012.